CN105617024A - 一种治疗银屑病的中药组合物及其制备方法 - Google Patents
一种治疗银屑病的中药组合物及其制备方法 Download PDFInfo
- Publication number
- CN105617024A CN105617024A CN201610095294.XA CN201610095294A CN105617024A CN 105617024 A CN105617024 A CN 105617024A CN 201610095294 A CN201610095294 A CN 201610095294A CN 105617024 A CN105617024 A CN 105617024A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- extract
- medicine composition
- parts
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 44
- 239000000203 mixture Substances 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 201000004681 Psoriasis Diseases 0.000 title abstract description 14
- 241000241413 Propolis Species 0.000 claims abstract description 21
- 229940069949 propolis Drugs 0.000 claims abstract description 21
- 241000374766 Dioscorea panthaica Species 0.000 claims abstract description 16
- 235000009926 Dioscorea panthaica Nutrition 0.000 claims abstract description 16
- 241001517299 Bulbophyllum Species 0.000 claims abstract description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 54
- 239000000284 extract Substances 0.000 claims description 42
- 238000011282 treatment Methods 0.000 claims description 30
- 230000001185 psoriatic effect Effects 0.000 claims description 25
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 24
- 239000000843 powder Substances 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- 238000000605 extraction Methods 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 14
- 239000007788 liquid Substances 0.000 claims description 12
- 239000006071 cream Substances 0.000 claims description 11
- 238000010992 reflux Methods 0.000 claims description 10
- 238000001291 vacuum drying Methods 0.000 claims description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 8
- 238000013461 design Methods 0.000 claims description 7
- 239000012467 final product Substances 0.000 claims description 7
- 239000012567 medical material Substances 0.000 claims description 7
- 239000008213 purified water Substances 0.000 claims description 7
- 238000004064 recycling Methods 0.000 claims description 7
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical class CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 claims description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 6
- 239000003480 eluent Substances 0.000 claims description 6
- 239000012530 fluid Substances 0.000 claims description 6
- 238000000227 grinding Methods 0.000 claims description 6
- 238000005520 cutting process Methods 0.000 claims description 5
- 239000000706 filtrate Substances 0.000 claims description 5
- 238000004108 freeze drying Methods 0.000 claims description 5
- 239000007921 spray Substances 0.000 claims description 5
- 238000004659 sterilization and disinfection Methods 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 claims description 3
- 238000002481 ethanol extraction Methods 0.000 claims description 3
- 239000000377 silicon dioxide Substances 0.000 claims 1
- 239000013641 positive control Substances 0.000 abstract description 24
- 210000004185 liver Anatomy 0.000 abstract description 23
- 241000699670 Mus sp. Species 0.000 abstract description 13
- 230000011278 mitosis Effects 0.000 abstract description 9
- 210000000981 epithelium Anatomy 0.000 abstract description 8
- 238000012449 Kunming mouse Methods 0.000 abstract description 6
- 230000002401 inhibitory effect Effects 0.000 abstract description 5
- 230000001737 promoting effect Effects 0.000 abstract description 5
- 230000015572 biosynthetic process Effects 0.000 abstract description 2
- 230000006378 damage Effects 0.000 abstract description 2
- 241001076416 Dendrobium tosaense Species 0.000 abstract 1
- 241000522190 Desmodium Species 0.000 abstract 1
- 229940079593 drug Drugs 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 239000008280 blood Substances 0.000 description 10
- 229920002472 Starch Polymers 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008107 starch Substances 0.000 description 9
- 235000019698 starch Nutrition 0.000 description 9
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 8
- 239000002671 adjuvant Substances 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 238000003304 gavage Methods 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 210000001215 vagina Anatomy 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 230000003203 everyday effect Effects 0.000 description 7
- 241000581650 Ivesia Species 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 235000019634 flavors Nutrition 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 239000011230 binding agent Substances 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000006187 pill Substances 0.000 description 5
- 231100000614 poison Toxicity 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 4
- 108010010803 Gelatin Chemical class 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 239000008273 gelatin Chemical class 0.000 description 4
- 229920000159 gelatin Chemical class 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 238000005469 granulation Methods 0.000 description 4
- 230000003179 granulation Effects 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- 206010000087 Abdominal pain upper Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 241000830536 Tripterygium wilfordii Species 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 239000002932 luster Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000000394 mitotic effect Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 239000007779 soft material Substances 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000011287 therapeutic dose Methods 0.000 description 3
- 230000035922 thirst Effects 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- 241000256837 Apidae Species 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000002202 Polyethylene glycol Chemical class 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000001913 cellulose Chemical class 0.000 description 2
- 229920002678 cellulose Chemical class 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 229960001338 colchicine Drugs 0.000 description 2
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 2
- 229960000452 diethylstilbestrol Drugs 0.000 description 2
- 238000007598 dipping method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 229920001223 polyethylene glycol Chemical class 0.000 description 2
- 230000001047 pyretic effect Effects 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 230000007863 steatosis Effects 0.000 description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 description 2
- 235000015398 thunder god vine Nutrition 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 241000256844 Apis mellifera Species 0.000 description 1
- 208000027496 Behcet disease Diseases 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- 239000003390 Chinese drug Substances 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 244000227573 Desmodium styracifolium Species 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000234272 Dioscoreaceae Species 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- KWKVAGQCDSHWFK-VNKDHWASSA-N Methyl sorbate Chemical compound COC(=O)\C=C\C=C\C KWKVAGQCDSHWFK-VNKDHWASSA-N 0.000 description 1
- 101000874159 Mus musculus Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial Proteins 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 235000019082 Osmanthus Nutrition 0.000 description 1
- 241000333181 Osmanthus Species 0.000 description 1
- 241000430993 Pholidota yunnanensis Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 206010040849 Skin fissures Diseases 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 206010043458 Thirst Diseases 0.000 description 1
- 241000545405 Tripterygium Species 0.000 description 1
- 208000009911 Urinary Calculi Diseases 0.000 description 1
- 206010047531 Visual acuity reduced Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 230000002431 foraging effect Effects 0.000 description 1
- 210000002503 granulosa cell Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000000643 oven drying Methods 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 231100000748 severe hepatic injury Toxicity 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8984—Dendrobium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
- A61K35/644—Beeswax; Propolis; Royal jelly; Honey
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/37—Celastraceae (Staff-tree or Bittersweet family), e.g. tripterygium or spindletree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/35—Extraction with lipophilic solvents, e.g. Hexane or petrol ether
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Insects & Arthropods (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明公开了一种治疗银屑病的中药组合物及其制备方法。该组合物是由广金钱草、雷公藤、蜂胶、铁皮石斛、石枣子、黄山药为原料制备而成的,对昆明种小鼠阴道上皮有丝分裂均有显著的抑制作用,对C57小鼠尾部鳞片颗粒层形成有显著的促进作用,且本发明对肝脏的损伤较阳性对照小。
Description
技术领域
本发明涉及医药卫生领域,具体涉及一种治疗银屑病的中药组合物及其制备方法。
背景技术
银屑病是一种常见的慢性复发性炎症性皮肤病,典型皮损为红斑、鳞屑,由此传统中医学也称之为“白疕”“松皮癣”。银屑病该病在我国的发病率高,有研究表明我国银屑病患者占世界人口的3%左右,且有逐年增长的趋势。银屑病皮肤受损明显,自觉瘙痒,常反复发作,迁延难愈,因此只能通过药物控制,使用药物防治每次发作,尽可能延长其缓解时间。
另一方面,皮肤病专家们普遍认可的治疗银屑病适合使用中西药结合方法治疗,又因为西药的副作用较大,因此较倾向于使用中药制剂作为银屑病人的长期治疗控制药。其中,雷公藤为能有效治疗银屑病的常用药物,但是雷公藤的活性成分同时也是毒性成分,对人体具有严重的毒副作用,不利于长期服用。
因此需要开发出适合的中药组合来降低雷公藤的毒性,从而有效的减轻病人的病症。
发明内容
本发明的目的是提供一种治疗银屑病的中药组合物;
本发明的另一目的是提供一种治疗银屑病的中药组合物的制备方法。
本发明的目的是通过下列的技术方案实现的:
本发明所述的治疗银屑病的中药组合物,是由如下重量份的原料制备而成的:广金钱草15~30份、雷公藤15~25份、蜂胶0.2~0.6份、铁皮石斛6~12份,石枣子25~40份,黄山药10~32份。
优选地,是由以下重量份的原料制备而成的:
广金钱草21份、雷公藤20份、蜂胶0.6份、铁皮石斛10份,石枣子32份,黄山药25份。
以下是本发明的药材来源:
铁皮石斛:本品为兰科植物铁皮石斛DendrobiumofficinaleKimuraetMigo的干燥茎。11月至翌年3月采收,除去杂质,剪去部分须根,烘干。或切成段,干燥或低温烘干。【性味与归经】甘,微寒。归胃、肾经。【功能与主治】益胃生津,滋阴清热。用于热病津伤,口干烦渴,胃阴不足,食少于呕,病后虚热不退,阴虚火旺,骨蒸劳热,目暗不明,筋骨痿软。现代药理研究表明,铁皮石斛还具有抗氧化、增强免疫力等作用。
石枣子:本品为兰科植物云南石仙桃PholidotayunnanensisRolfe的假鳞茎
或全草。9~10月采收,鲜用或切片晒干。【性味归经】甘、淡、凉。【功能与
主治】清热润肺,散结消肿。主治肺痨咳血,肺热咳嗽,胃痛,肋痛,疮疡肿毒。
雷公藤:本品为卫矛科雷公藤属植物雷公藤TripterygiumwilfordiiHook.f.的根的木质部,秋季挖取根部,晒干或去皮晒干。【性味与归经】苦、辛、凉,大毒。【功能与主治】祛风除湿,杀虫,解毒。主治类风湿关节炎,风湿性关节炎,肾小球肾炎,肾病综合征,红斑狼疮,口咽干燥综合征,白塞病,湿疹,银屑病,麻风病,疥疮。现代药理研究表明,雷公藤具有抗炎、抗病原微生物等作用。
蜂胶:本品为蜜蜂科昆虫意大利蜂ApismilliferaL.工蜂采集的植物树脂与其上颚腺、蜡腺等分泌物混合形成的具有黏性的固体胶状物。多为夏、秋季自峰箱中收集,除去杂质。【性味与归经】辛、苦、寒。归脾、胃经。【功能与主治】补虚弱,化浊脂,止消渴;外用解毒消肿,收敛生肌。用于体虚早衰,高脂血症,消渴;外治皮肤皲裂,烧烫伤。现代药理研究表明,蜂胶还具有促进组织修复、抗肿瘤等作用。
广金钱草:本品为豆科植物广金钱草Desmodiumstyracifolium(Osb.)Merr.的干燥地上部分。夏,秋二季采割,除去杂质,晒干。【性味与归经】甘、淡、凉。归肝、肾、膀胱经。【功能与主治】利湿退黄,利尿通淋。用于黄疸尿赤,热淋,石淋,小便涩痛,水肿尿少。
黄山药:本品为薯蓣科植物黄山药DioscoreapanthaicaPrainetBurk.的干燥根茎。秋季采挖,除去须根,洗净,切片,晒干。【性味与归经】苦、微辛,平。归胃、心经。【功能与主治】理气止痛,解毒消肿。用于胃痛,吐泻腹痛,跌打损伤,外治疮痈肿毒。
本发明的另一方面是提供了本发明活性成分的制备方法,该方法是采用部分药材全粉加入,另一部分药材通过纯化水或50-95%体积百分浓度的乙醇提取,混合而得。具体的制备方法如下:
(1)铁皮石斛干燥,与蜂胶混合粉碎,细粉备用;
(2)广金钱草、石枣子、黄山药加水提取后,提取物备用;
(3)雷公藤用50%-95%体积百分浓度的乙醇提取制备,提取物备用;
(4)步骤1-3所得细粉及提取物混合粉碎,即得。
优选地,步骤(1)所述粉碎方法为:将鲜铁皮石斛净选、切段、喷70‐80%乙醇消毒,与蜂胶混匀,冷冻干燥。
优选地,步骤(2)所述提取方法为;取广金钱草、石枣子、黄山药,加药材重量8‐15倍的纯化水加热回流提取3‐4次,每次提取时间为1‐3小时,合并提取液,滤过,滤液浓缩至60‐80℃时相对密度为1.05‐1.20的流浸膏,于真空低温干燥得到水提取物干膏。
优选地,步骤(3)所述提取方法为:取雷公藤粉碎成粗粉,加体积百分浓度90%以上的乙醇加热回流提取,提取2~4次,每次2~5小时,过滤,合并提取液,回收乙醇,得到雷公藤浸膏,用氯仿萃取该浸膏3~5次,浓缩后,过硅胶‐中性氧化铝层析柱,用二氯乙烷洗脱,弃去洗脱液,再用乙醇:二氯乙烷=1:99洗脱,收集洗脱液,回收溶剂,真空干燥得干膏。
优选地,步骤(3)所述提取方法为:取雷公藤粉碎成粗粉,50%乙醇回流提取,提取2~4次,每次2~4小时,过滤,合并提取液,回收乙醇,得到雷公藤浸膏,用乙酸乙酯萃取该浸膏3~5次,取乙酸乙酯层,回收溶剂,真空干燥得干膏。
优选地,步骤(4)所述混合粉碎为:将步骤(1)-(3)所述细粉与提取物通过低温超微粉碎机粉碎成极细粉,即得。
本发明所述的治疗银屑病的中药制剂,可以与医药学上可接受的载体配合,制成各种常用制剂,如片剂、颗粒剂、微丸、丸剂等。
本发明的药学上可接受的载体包括但不限于以下:
稀释剂:淀粉、糖粉、乳糖、糊精、微晶纤维素、无机盐、糖醇类等。
润湿剂与粘合剂:纯化水、乙醇、明胶、聚乙二醇、纤维素衍生物等。
崩解剂:淀粉、羧甲基淀粉钠、纤维素衍生物、交联聚维酮等。
润滑剂:硬脂酸镁、微粉硅胶、滑石粉、聚乙二醇等。
助溶剂:水、乙醇、甘油、丙二醇、液状石蜡、植物油等。
矫味剂:蔗糖、单糖、芳香剂等。
防腐剂:苯甲酸、山梨酸、甲酯、乙酯、丙酯等。
方法1:颗粒剂
取混合所得活性成分,加入颗粒剂常用辅料,按常规生产方法制备得本发明颗粒剂。
上述颗粒剂常用辅料包括稀释剂、润湿剂、粘合剂之一或全部。
方法2:片剂
取混合所得活性成分,加入片剂常用辅料,按常规生产方法制备得本发明片剂。
上述片剂常用辅料包括稀释剂、润湿剂、粘合剂、崩解剂、润滑剂之一或全部。
方法3:微丸
取混合所得活性成分,加入微丸常用辅料,按常规生产方法制备得本发明微丸。
上述微丸常用辅料包括稀释剂、粘合剂、润滑剂之一或全部。
方法4:丸剂
取混合所得活性成分,加入丸剂常用辅料,按常规生产方法制备得本发明丸剂。
上述丸剂常用辅料包括稀释剂、润湿剂、粘合剂、润滑剂之一或全部。
方解:银屑病是一种慢性炎症性皮肤病,中医称之为“白疕”、“顽癣”“牛皮癣”。目前《中医诊断学》《中医外科学》总结得出,银屑病中医辨证分为血热内蕴正、血虚风燥证、气血瘀滞证、脾虚湿盛证。即银屑病由于风邪侵袭,使得营卫不和,气血不畅,阻于肌表,日久化热,湿邪化燥导致燥热成毒,热毒走至肌表而致。方中的君药雷公藤具有性凉,祛风除湿之效,可以祛血热,除风湿,使得气机顺畅。臣以蜂胶补虚弱,止消渴,疏风祛湿,解毒补虚,消除血虚之证。佐以广金钱草、石枣子、黄山药、铁皮石斛以其清肺热,养胃滋阴之功,使得气机、脾胃运化正常,增强雷公藤的祛风除湿之功。
现在药理研究表明,本发明的方剂中的雷公藤是银屑病的常用有效治疗药物,但毒副作用较强。同时,蜂胶也具有治疗银屑病的作用,且能消炎生肌,二者联合使用可以增强治疗银屑病之功。另一方面,蜂胶、广金钱草、石枣子、黄山药、铁皮石斛具有较强的清血热、保护免疫系统以及促进组织修复的药物,从而降低雷公藤的毒副作用,使得该方剂能长期地运用到银屑病的控制中。
本发明提供的一种治疗银屑病的中药组合物具有以下优点:
1、本发明在治疗银屑病时具有较为明显的作用且毒性较低。在小鼠阴道上皮有丝分裂实验中,服用本发明的各组及阳性对照组,和空白对照组比较,具有显著性差异(p<0.01),高剂量组、治疗组与阳性对照组相比无统计学意义(p>0.05),说明本发明对昆明种小鼠阴道上皮有丝分裂均有显著的抑制作用。
2、在鼠尾部鳞片颗粒层形成实验中,服用本发明的各组、阳性对照组,和空白对照组比较,具有显著性差异(p<0.01),服用本发明的高剂量组、治疗组与阳性对照组相比无统计学意义(p>0.05),说明本发明对C57小鼠尾部鳞片颗粒层形成有显著的促进作用。
3、在鼠尾部鳞片颗粒层形成实验中,服用本发明的低剂量组、治疗组的血清中的AST及ALT与空白组无显著性差异(p>0.05),同时肝脏的病理切片光镜检查发现本发明对肝脏的损伤较阳性对照小。
4、本发明的中药组合物,配伍合理创新,效果较佳、毒性较低。
具体实施方式
下面通过实施例进一步说明本发明。应该理解的是,本发明的实施例是用于说明本发明而不是对本发明的限制。根据本发明的实质对本发明进行的简单改进都属于本发明要求保护的范围。
实施例1
将鲜铁皮石斛6kg净选、切段、喷75%乙醇消毒,与蜂胶0.2kg一起置于真空冷冻干燥机冷冻干燥;
取广金钱草15kg、石枣子25kg、黄山药10kg,加10倍纯化水回流提取3次,每次提取时间为分别3小时、2小时、1小时,合并提取液,滤过,滤液浓缩至60‐80℃时相对密度为1.05‐1.20的流浸膏,于真空干燥机内低温干燥得到水提取物干膏;
取雷公藤15kg粉碎成粗粉,95%乙醇回流提取,提取2次,每次分别为5小时、2小时,过滤,合并提取液,回收乙醇,得到雷公藤浸膏,用氯仿萃取该浸膏3次,浓缩后,过硅胶‐中性氧化铝(1:1)层析柱,用二氯乙烷洗脱,弃去洗脱液,再用乙醇:二氯乙烷(1:99)洗脱,收集洗脱液,回收溶剂,真空干燥得干膏。
将已经干燥的铁皮石斛、蜂胶、水提取物干膏和雷公藤干膏通过低温超微粉碎机粉碎成极细粉,加入适量的淀粉、微晶纤维素、明胶、羧甲基淀粉钠、硬脂酸镁、微粉硅胶、蔗糖,混合均匀,制软材、制粒、压制成片即得。
实施例2
将鲜铁皮石斛12kg净选、切段、喷70%乙醇消毒,与蜂胶0.6kg一起置于冷冻干燥机冷冻干燥;
取广金钱草30kg、石枣子40kg、黄山药32kg,加10倍纯化水热浸提取4次,每次浸提3小时,合并提取液,滤过,滤液浓缩至60‐80℃时相对密度为1.05‐1.20的流浸膏,真空干燥得到水提取物干膏;
取雷公藤25kg粉碎成粗粉,50%乙醇回流提取,提取4次,每次4小时,过滤,合并提取液,回收乙醇,得到雷公藤浸膏,用乙酸乙酯萃取该浸膏5次,取乙酸乙酯层,回收溶剂,真空干燥得干膏。
将已经干燥的铁皮石斛、蜂胶、水提取物干膏和雷公藤干膏通过低温超微粉碎机粉碎成极细粉,加入适量的淀粉、微晶纤维素、明胶、羧甲基淀粉钠、硬脂酸镁、微粉硅胶、蔗糖,混合均匀,制软材、制粒、压制成片即得。
实施例3:
将鲜铁皮石斛10kg净选、切段、喷80%乙醇消毒,与蜂胶0.4kg一起置于冷冻干燥机冷冻干燥;
取广金钱草21kg、石枣子32kg、黄山药25kg,加10倍纯化水热浸提取4次,每次浸提3小时,合并提取液,滤过,滤液浓缩至60‐80℃时相对密度为1.05‐1.20的流浸膏,真空干燥得到水提取物干膏;
取雷公藤20kg粉碎成粗粉,50%乙醇回流提取,提取4次,每次4小时,过滤,合并提取液,回收乙醇,得到雷公藤浸膏,用乙酸乙酯萃取该浸膏3次,取乙酸乙酯层,回收溶剂,真空干燥得干膏。
将已经干燥的铁皮石斛、蜂胶、水提取物干膏和雷公藤干膏通过低温超微粉碎机粉碎成极细粉,加入适量的淀粉、微晶纤维素、明胶、羧甲基淀粉钠、硬脂酸镁、微粉硅胶、蔗糖,混合均匀,制软材、制粒、压制成片即得。
药效学试验:
1实验材料
1.1动物
健康SPF级昆明种雌性小鼠80只,体重18‐22g,由广西医科大学医学实验动物中心提供,许可证号SCXKG桂2003‐0003。C57BL/6J80只,体重18‐22g,雌雄各半,由广州中医药大学实验动物中心提供,动物合格证号:粤医实动准字第A006号。
1.2受试样品与试剂
本发明实施例1、2。
雷公藤多苷片,10ng/片
己烯雌酚注射液,2mg/ml
秋水仙碱
苦味酸
碘酒
10%福尔马林
HE染色液
2实验分组及给药方法
分别为空白组、阳性对照组、高剂量组、治疗组、低剂量组。
空白对照组:给予生理盐水,
治疗组:小鼠分别给予实施例1、2制备的样品,给药量按药材生药量7.75g/kg计,每天灌胃1次。
高剂量组:小鼠分别给予实施例1、2制备的样品,给药量按药材生药量15.5g/kg计,每天灌胃1次。
低剂量组:小鼠分别给予实施例1、2制备的样品,给药量按药材生药量3.88g/kg计,每天灌胃1次。
阳性对照组:小鼠分别给予雷公藤多苷片1.5mg/kg,每天灌胃1次。
给药方法:每天灌胃1次,连续28d。
3实验方法
3.1实验一:昆明种小鼠阴道上皮模型制模给昆明种小鼠ip己烯雌酚,02mg/次,1次/日,连续3天,使所有小鼠处于雌激素期,制模成功后随机分成8组,每组10只,分别标记为空白组、阳性对照组、高剂量组、治疗量组、低剂量组。空白组每天给予与治疗组等剂量的生理盐水灌胃,各组按上述的给药量及给药方法给与相应的受试物。第28d统一给药后一个小时后,每只小鼠腹腔注射秋水仙碱2mg/kg,4h后杀死小鼠,取阴道标本以体积分数10%福尔马林固定,石蜡包埋,HE染色。用光学显微镜观察细胞有丝分裂,计数300个基底细胞的有丝分裂数,并算出每100个细胞的有丝分裂数,成为有丝分裂指数。
3.2实验二:取C57BL/6J小鼠雌雄各40只,随机分成8组,每组10只,分别标记为空白组,阳性对照组,高剂量组,治疗量组,低剂量组,空白组每天给予与治疗组等剂量的生理盐水灌胃,各组按上述的给药量及给药方法给与相应的受试物。在第28d灌胃24h后,称重,摘眼球取血,脱颈椎处死小鼠,取样检测下列指标:①取距离尾根约2cm处尾背面皮肤一长条。用体积分数为10%福尔马林固定,石蜡包埋,HE染色。在光学显微镜下逐一观察每只小鼠的尾部鳞片。凡是一个鳞片有连接成行的颗粒层细胞者,称为有颗粒层的鳞片。计数每100个鳞片中有颗粒层的鳞片数。②解剖小鼠,解剖观察肝脏的颜色及大小,取肝,称肝湿重,并计算肝脏系数。肝脏系数=肝湿重(g)/体重(g)×100%,再将肝脏用10%福尔马林固定,石蜡包埋,HE染色,使用光学显微镜进行病理观察。所取血液离心取血请,检测血清的ALT和AST含量。
3.3实验数据统计分析
采用方差分析比较各变量间的差别,如果方差齐性或正态性不能满足方差分析的要求则改用H检验。
4.实验结果
4.1小鼠阴道上皮有丝分裂的影响结果见表1。
表1本发明对昆明种小鼠阴道上皮有丝分裂的影响
注:与空白组相比:*P<0.01;与阳性对照组相比:#P<0.05
表1结果显示:服用本发明的各组及阳性对照组,和空白对照组比较,具有显著性差异(p<0.01),治疗组、高剂量组及阳性对照组的抑制作用较强,高剂量组、治疗组与阳性对照组相比无统计学意义(p>0.05),说明本发明对昆明种小鼠阴道上皮有丝分裂均有显著的抑制作用。
4.2小鼠尾部鳞片颗粒层形成的影响结果见表2。
表2本发明对C57小鼠尾部鳞片颗粒层形成的影响
注:与空白组相比:*P<0.01;与阳性对照组相比:#P<0.05
表2结果显示:服用本发明的各组、阳性对照组,和空白对照组比较,具有显著性差异(p<0.01),服用本发明的高剂量组、治疗组与阳性对照组相比无统计学意义(p>0.05),说明本发明对C57小鼠尾部鳞片颗粒层形成有显著的促进作用。
4.3小鼠血清ALT、AST的比较见表3
表3本发明对各组小鼠血清ALT、AST的影响
注:与空白组相比:*P<0.01,**P<0.05;与阳性对照组相比:#P<0.01,##P<0.05
表3结果显示:服用本发明的低剂量组、治疗组的AST和空白对照组的相比,无显著性差异(P>0.05),与阳性对照相比具有显著性意义(P<0.01);治疗组及低剂量组的ALT与空白组相比,没有显著性差异(P>0.05)。服用本发明的各组与阳性对照组相比,均具有显著性差异(P<0.01);服用本发明的各组的肝脏系数与空白组相比没有显著性差异(P>0.05),与阳性对照组具有显著性差异(P<0.05)。同时肝脏的病理切片显示,空白组的肝脏形态正常,色泽鲜红,质地柔软,肝索排列规则,肝小叶分界清楚,细胞结构清晰。与空白组相比,服用本发明的低、治疗剂量组的肝脏形态基本正常,色泽较红,质地柔软,无明显病变,肝索排列轻度絮乱,肝小叶分界尚清楚,肝细胞伴有少量水肿和脂肪变性。高剂量组及阳性对照组肝脏体积较空白组略大,色泽稍暗,个别表面呈细小颗粒状。阳性对照组的肝脏肝索排列絮乱,肝小叶分界不清,水肿及脂肪变性明显。
结论:研究表明,本发明具有治疗银屑病的作用,在小鼠阴道上皮有丝分裂实验中,服用本发明的各组均对小鼠阴道上皮有丝分裂具有显著的抑制作用;在小鼠尾部鳞片颗粒层形成实验结果中可以看到,服用本发明的各组对小鼠尾部鳞片颗粒层形成具有促进作用,并且没有阳性对照组的严重肝脏损伤作用。所以可以证明本发明具有治疗银屑病的作用,且能显著性减轻雷公藤对肝脏的不良副作用。
虽然,上文中已经用一般性说明、具体实施方式及试验,对本发明作了详尽的描述,但在本发明基础上,可以对之作一些修改或改进,这对本领域技术人员而言是显而易见的。因此,在不偏离本发明精神的基础上所做的这些修改或改进,均属于本发明要求保护的范围。
Claims (9)
1.一种治疗银屑病的中药组合物,其特征在于它是由如下重量份的中药原料制备而成的:广金钱草15~30份、雷公藤15~25份、蜂胶0.2~0.6份、铁皮石斛6~12份,石枣子25~40份,黄山药10~32份。
2.如权利要求1所述的治疗银屑病的中药组合物,其特征在于它是由如下重量份的中药原料制备而成的:广金钱草21份、雷公藤20份、蜂胶0.6份、铁皮石斛10份,石枣子32份,黄山药25份。
3.如权利要求1或2所述的治疗银屑病的中药组合物,其特征在于,其活性成分是通过以下步骤制备而成:
(1)铁皮石斛干燥,与蜂胶混合粉碎,细粉备用;
(2)广金钱草、石枣子、黄山药加水提取后,提取物备用;
(3)雷公藤用50%-95%体积百分浓度的乙醇提取制备,提取物备用;
(4)步骤1-3所得细粉及提取物混合粉碎,即得。
4.如权利要求3所述的治疗银屑病的中药组合物,其特征在于步骤(1)所述粉碎方法为:将鲜铁皮石斛净选、切段、喷70-80%乙醇消毒,与蜂胶混匀,冷冻干燥。
5.如权利要求3所述的治疗银屑病的中药组合物,其特征在于步骤(2)所述提取方法为;取广金钱草、石枣子、黄山药,加药材重量8-15倍的纯化水加热回流提取3-4次,每次提取时间为1-3小时,合并提取液,滤过,滤液浓缩至60-80℃时相对密度为1.05-1.20的流浸膏,于真空低温干燥得到水提取物干膏。
6.如权利要求3所述的治疗银屑病的中药组合物,其特征在于步骤(3)所述提取方法为:取雷公藤粉碎成粗粉,加体积百分浓度90%以上的乙醇加热回流提取,提取2~4次,每次2~5小时,过滤,合并提取液,回收乙醇,得到雷公藤浸膏,用氯仿萃取该浸膏3~5次,浓缩后,过硅胶-中性氧化铝层析柱,用二氯乙烷洗脱,弃去洗脱液,再用乙醇:二氯乙烷=1:99洗脱,收集洗脱液,回收溶剂,真空干燥得干膏。
7.如权利要求3所述的治疗银屑病的中药组合物,其特征在于步骤(3)所述提取方法为:取雷公藤粉碎成粗粉,50%乙醇回流提取,提取2~4次,每次2~4小时,过滤,合并提取液,回收乙醇,得到雷公藤浸膏,用乙酸乙酯萃取该浸膏3~5次,取乙酸乙酯层,回收溶剂,真空干燥得干膏。
8.如权利要求3所述的治疗银屑病的中药组合物,其特征在于步骤(4)所述混合粉碎为:将步骤(1)-(3)所述细粉与提取物通过低温超微粉碎机粉碎成极细粉,即得。
9.一种治疗银屑病的中药制剂,由权利要求1或2所述的治疗银屑病的中药组合物与医药行业上可接受的载体配合制备而成。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610095294.XA CN105617024B (zh) | 2016-02-22 | 2016-02-22 | 一种治疗银屑病的中药组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610095294.XA CN105617024B (zh) | 2016-02-22 | 2016-02-22 | 一种治疗银屑病的中药组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105617024A true CN105617024A (zh) | 2016-06-01 |
CN105617024B CN105617024B (zh) | 2019-12-13 |
Family
ID=56032631
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610095294.XA Active CN105617024B (zh) | 2016-02-22 | 2016-02-22 | 一种治疗银屑病的中药组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105617024B (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101461833A (zh) * | 2009-01-13 | 2009-06-24 | 牛付立 | 一种治疗银屑病的外用药物组合物 |
CN102688283A (zh) * | 2012-06-15 | 2012-09-26 | 复旦大学附属中山医院 | 一种治疗红斑狼疮的中药胶囊及其制备方法 |
CN103006712A (zh) * | 2013-01-08 | 2013-04-03 | 陈维太 | 一种抗氧化清除自由基的蜂产品提取物 |
CN103751280A (zh) * | 2011-10-13 | 2014-04-30 | 何克诚 | 一种治疗牛皮癣的药物组成物 |
CN105079064A (zh) * | 2015-07-30 | 2015-11-25 | 无限极(中国)有限公司 | 一种中药提取物及其制备方法与应用 |
-
2016
- 2016-02-22 CN CN201610095294.XA patent/CN105617024B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101461833A (zh) * | 2009-01-13 | 2009-06-24 | 牛付立 | 一种治疗银屑病的外用药物组合物 |
CN103751280A (zh) * | 2011-10-13 | 2014-04-30 | 何克诚 | 一种治疗牛皮癣的药物组成物 |
CN102688283A (zh) * | 2012-06-15 | 2012-09-26 | 复旦大学附属中山医院 | 一种治疗红斑狼疮的中药胶囊及其制备方法 |
CN103006712A (zh) * | 2013-01-08 | 2013-04-03 | 陈维太 | 一种抗氧化清除自由基的蜂产品提取物 |
CN105079064A (zh) * | 2015-07-30 | 2015-11-25 | 无限极(中国)有限公司 | 一种中药提取物及其制备方法与应用 |
Also Published As
Publication number | Publication date |
---|---|
CN105617024B (zh) | 2019-12-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zheng et al. | Ephedrae herba: A comprehensive review of its traditional uses, phytochemistry, pharmacology, and toxicology | |
CN102178804B (zh) | 一种治疗肛周湿疹的中药组合物及其制备方法 | |
CN102240372B (zh) | 一种治疗痛风性关节炎和高尿酸血症的药物及制备方法 | |
CN105535439A (zh) | 一种治疗咽炎的中药组合物及其制备方法 | |
CN103655858A (zh) | 一种治疗痔疮的中药制剂——三七三黄软膏,栓及洗剂 | |
CN103479963A (zh) | 一种治疗类风湿关节炎的中药胶囊及其制备方法 | |
CN103285179B (zh) | 一种治疗急性咽炎的中药制剂及其制备方法 | |
CN102000164A (zh) | 一种治疗银屑病的中药组合物及其制备方法 | |
CN101933973A (zh) | 防治肝损伤的药物组合物 | |
CN101744931A (zh) | 祛痤疮的中药组合物、其制剂、制备方法及用途 | |
CN106728898A (zh) | 一种修复皮肤屏障的药物组合物及其制备方法 | |
CN102652819B (zh) | 一种妇炎康分散片及其制备方法 | |
CN101850063A (zh) | 一种防治痛风的药物制剂及其制备方法 | |
CN101342249A (zh) | 一种治疗乙肝的中药制剂及其制备方法 | |
CN105617024A (zh) | 一种治疗银屑病的中药组合物及其制备方法 | |
CN106620541A (zh) | 一种治疗慢性湿疹的外用中药组合物及其制备方法 | |
CN102178749A (zh) | 一种中药组合物及其制备方法 | |
CN105213669A (zh) | 一种治疗结节性血管炎的中药及制备方法 | |
CN105748685B (zh) | 一种脚气抑菌剂及其制备方法 | |
CN104383050A (zh) | 一种内外结合治疗风湿性关节炎的药物及制备方法 | |
CN104306784A (zh) | 一种用于治疗风湿性关节炎的中药组合物及其制备方法和应用 | |
CN103656323A (zh) | 一种治疗红皮症型牛皮癣的中药 | |
CN103127358B (zh) | 一种治疗类风湿关节炎的中药组合物及其制备方法 | |
CN102188681B (zh) | 一种用于治疗盆腔炎的中药组合物及其制备方法和应用 | |
CN115475200B (zh) | 一种治疗肝纤维化的中药复方制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |